## Claims

1. A pharmaceutical composition comprising (i) a therapeutic compound, and (ii) a vanilloid receptor-1 (VR1) agonist.

2. The pharmaceutical composition of claim 1, wherein said composition is suitable for ingestion.

3. The pharmaceutical composition of claim 1 or 2, wherein said composition is formulated for controlled release.

4. The pharmaceutical composition of any of claims 1-3, wherein said VR1 agonist is selected from the group consisting of capsaicin, resiniferatoxin, olvanil, piperine, zingerone, anandamide, 12- and 15-(S)-hydroperoxy-eicosatetraenoic acids, 5- and 15-(S)-hydroxyeicosatetraenoic acids, phorbol 12-phenylacetate 13-acetate 20-homovanillate, 2 phorbol 12,13-didecanoate 20-homovanillate, leukotriene B(4), N-(3-acyloxy-2-benzylpropyl)-N'-dihydroxytetrahydrobenzazepine, and tetrahydroisoquinoline thiourea analogs.

5. The pharmaceutical composition of claims 4, wherein said VR1 agonist is capsaicin.

6. The pharmaceutical composition of claims 4, wherein said VR1 agonist is resiniferatoxin.

7. The pharmaceutical composition of any of claims 1-6, wherein said therapeutic compound is an opioid.

8. The pharmaceutical composition of claim 7, wherein said opioid is morphine, oxycodone, or hydrocodone.

9. The pharmaceutical composition of any of claims 1-6, wherein said therapeutic compound is selected from the group consisting of morphine, oxycodone, hydrocodone, hydromorphone, levorphanol, buprenorphine, butorphanol, fentanyl, dipipanone, codeine, dihydrocodeine, tramadol, etorphine, dihydroetorphine, meperidine, methadone, propoxyphene, and heroin.

10. The pharmaceutical composition of any of claims 1-6, wherein said therapeutic compound is a cannabinoid, an amphetamine, or a benzodiazepine.

11. A method for controlling administration of a therapeutic compound comprising mixing said therapeutic compound and a vanilloid receptor-1 (VR1) agonist in the same pharmaceutical composition.

12. The method of claim 11, wherein said pharmaceutical composition is suitable for ingestion.

13. The method of claim 11 or 12, wherein said pharmaceutical composition is formulated for controlled release.

14. The method of any of claims 11-13, wherein said VR1 agonist is selected from the group consisting of capsaicin, resiniferatoxin, olvanil, piperine, zingerone, anandamide, 12- and 15-(S)-hydroperoxy-eicosatetraenoic acids, 5- and 15-(S)-hydroxyeicosatetraenoic acids, phorbol 12-phenylacetate 13-acetate 20-homovanillate, 2 phorbol 12,13-didecanoate 20-homovanillate, leukotriene B(4), N-(3-acyloxy-2-benzylpropyl)-N'-dihydroxytetrahydrobenzazepine, and tetrahydroisoquinoline thiourea analogs.

15. The method of claim 14, wherein said VR1 agonist is capsaicin.

16. The method of claim 14, wherein said VR1 agonist is resiniferatoxin.

17. The method of any of claims 11-16, wherein said therapeutic compound is an opioid.

18. The method of claim 17, wherein said opioid is morphine, oxycodone, or hydrocodone.

19. The method of any of claims 11-16, wherein said therapeutic compound is selected from the group consisting of morphine, oxycodone, hydrocodone, hydromorphone, levorphanol, buprenorphine, butorphanol, fentanyl, dipipanone, codeine, dihydrocodeine, tramadol, etorphine, dihydroetorphine, meperidine, methadone, propoxyphene, and heroin.

20. The method of any of claims 11-16, wherein said therapeutic compound is a cannabinoid, an amphetamine, or a benzodiazepine.

21. A method of manufacturing a pharmaceutical composition comprising mixing a therapeutic compound and a vanilloid receptor-1 (VR1) agonist.

22. The method of claim 21, wherein said pharmaceutical composition is suitable for ingestion.

23. The method of claim 21 or 22, wherein said pharmaceutical composition is formulated for controlled release.

24. The method of any of claims 21-23, wherein said VR1 agonist is selected from the group consisting of capsaicin, resiniferatoxin, olvanil, piperine, zingerone, anandamide, 12- and 15-(S)-hydroperoxy-eicosatetraenoic acids, 5- and 15-(S)-hydroxyeicosatetraenoic acids, phorbol 12-phenylacetate 13-acetate 20-homovanillate, 2 phorbol 12,13-didecanoate 20-homovanillate, leukotriene B(4), N-(3-acyloxy-2-benzylpropyl)-N'-dihydroxytetrahydrobenzazepine, and tetrahydroisoquinoline thiourea analogs.

25. The method of claim 24, wherein said VR1 agonist is capsaicin.

26. The method of claims 24, wherein said VR1 agonist is resiniferatoxin.

27. The method of any of claims 21-26, wherein said therapeutic compound is an opioid.

28. The method of claim 27, wherein said opioid is morphine, oxycodone, or hydrocodone.

29. The method of any of claims 21-26, wherein said therapeutic compound is selected from the group consisting of morphine, oxycodone, hydrocodone, hydromorphone, levorphanol, buprenorphine, butorphanol, fentanyl, dipipanone, codeine, dihydrocodeine, tramadol, etorphine, dihydroetorphine, meperidine, methadone, propoxyphene, and heroin.

30. The method of any of claims 21-26, wherein said therapeutic compound is a cannabinoid, an amphetamine, or a benzodiazepine.